NIRAMAI COVID screening solution receives funding from UK's CDC Group

NIRAMAI Health Analytix, a deep-tech health startup known for its innovative AI and thermal-imaging-based breast cancer screening test, has announced receipt of research funding from CDC-UK for its new thermal-screening solution.

NIRAMAI is an investee of Pi Ventures, a fund backed by CDC Group (“CDC”, the UK’s development finance institution and impact investor). NIRAMAI FeverTest is a software that enables screening for Covid-19 symptoms in public places, using computer vision and AI to analyse and monitor crowd compliance with Covid-19 guidelines. Analysing infrared and visual cameras across multiple hospitals, corporate offices and public places, the software offers an automated screening solution